Next Article in Journal
Dysregulation of Endothelin-1: Implications for Health Disparities in Alzheimer’s Disease
Next Article in Special Issue
Drug-Drug Interactions Leading to Adverse Drug Reactions with Rivaroxaban: A Systematic Review of the Literature and Analysis of VigiBase
Previous Article in Journal
Exploring a Cost-Efficient Model for Predicting Cerebral Aβ Burden Using MRI and Neuropsychological Markers in the ADNI-2 Cohort
 
 
Article
Peer-Review Record

Evaluation of Phenotypic and Genotypic Variations of Drug Metabolising Enzymes and Transporters in Chronic Pain Patients Facing Adverse Drug Reactions or Non-Response to Analgesics: A Retrospective Study

J. Pers. Med. 2020, 10(4), 198; https://doi.org/10.3390/jpm10040198
by Victoria Rollason 1,2,*, Célia Lloret-Linares 3, Kuntheavy Ing Lorenzini 1,2, Youssef Daali 1,2, Marianne Gex-Fabry 4, Valérie Piguet 1, Marie Besson 1,2, Caroline Samer 1,2 and Jules Desmeules 1,2
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Reviewer 3: Anonymous
J. Pers. Med. 2020, 10(4), 198; https://doi.org/10.3390/jpm10040198
Submission received: 24 September 2020 / Revised: 22 October 2020 / Accepted: 24 October 2020 / Published: 27 October 2020
(This article belongs to the Special Issue Personalized Medicine: Pharmacokinetics)

Round 1

Reviewer 1 Report

Dear Authors,

Thank you for provising me with the oppurtunity to review your article. Generally, the quality of prsentation of the article is fine and the following comments can help you to improve its quality of presentation:

Please start the methods section with the recognition of the research design, in connection to the previously published research.

Ethical considerations applying to the research process should be fully described under a separate subheading.

Please make the figure colourful.

Good luck!

Author Response

Dear Reviewer, 

Thank you for your suggestions that have been very helpful. Please find below a point-by point answer:

Please start the methods section with the recognition of the research design, in connection to the previously published research.

Line 75-77. The paragraph "2.1. Patients and setting" was reorganised to mention the design of the study, with reference to the previously published study at the beginning of the paragraph.

Ethical considerations applying to the research process should be fully described under a separate subheading

Line 96-97. Ethical considerations were moved to a separate paragraph at the end of "2.1. Patients and setting" subheading

Please make the figure colourful

Line 244. This was done, we hope it looks better

Thank you again and kind regards

Reviewer 2 Report

Thw work is very interesting and well defined.I have only two minor requests

1) Improve the quality of Figure 1.

2) Improve the future perspetives in conclusions to underline the importance of obtained results.

Author Response

Dear Reviewer,

Thank you very much for your helpful suggestions. Please find below a point-by-point answer to your comments: 

Improve the quality of Figure 1

Line 244. This was done, we hope it looks better

Improve the future perspectives in conclusions to underline the importance of obtained results

Line 336-358. The conclusion and perspectives were improved

 Thank you again and kind regards

Reviewer 3 Report

This is a retrospective study in personalized medicine field and it reveals pharmacogenetic impact in adverse drug response and pharmacological resistance in patients taking analgesic drugs for chronic pain. In my opinion this study is of interest, clearly organized and well described, with novelty aspects. I think there is a bit of sorting out the description of enzymes you have investigated and it would be worth to indicate phase I, phase II enzymes and transporters. Additionally, it would be interested to shortly describe the involvement of studied enzymes in the metabolizing of given analgesic drug(s).

Author Response

Dear Reviewer,

Thank you very much for your helpful suggestions. Please find below a point-by-point answer to your comments:

This is a retrospective study in personalized medicine field and it reveals pharmacogenetic impact in adverse drug response and pharmacological resistance in patients taking analgesic drugs for chronic pain. In my opinion this study is of interest, clearly organized and well described, with novelty aspects. I think there is a bit of sorting out the description of enzymes you have investigated and it would be worth to indicate phase I, phase II enzymes and transporters.

Line 119-123. We clarified this in the section 2.3 by adding a paragraph better explaining the enzymes.

Additionally, it would be interested to shortly describe the involvement of studied enzymes in the metabolizing of given analgesic drug(s).

Line 121-126. We added a table describing the metabolic pathways of the analgesics regarding CYPs and a text explaining the COMT and P-gp.

Thank you again and kind regards

Back to TopTop